X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

In precisionFDA Challenge, PacBio HiFi Reads Outperform Both Short Reads and Noisy Long Reads

Tuesday, August 11, 2020

 width=

In the recent precisionFDA Truth Challenge V2, which evaluated methods for variant calling in human genomes, approaches that use PacBio HiFi reads delivered the highest precision and recall in all categories: genome-wide, specifically in difficult-to-map regions, and in the major histocompatibility complex (Figure 1).  The challenge had 64 total entries: 17 using PacBio HiFi reads, 24 using Illumina reads, 3 using Oxford Nanopore reads, and 20 using multiple technologies. Twenty-five of the 26 overall most accurate callsets used PacBio HiFi reads (12 PacBio-only, 13 multi-technology), including all of the top 12 (3 PacBio-only, 9 multi-technology).

A submission from Google DeepVariant using HiFi reads achieved the highest genome-wide accuracy of any single-technology callset, with better performance for single-nucleotide variants (SNVs) and indels and 5.8× fewer total errors than the popular combination of GATK with Illumina reads (Figure 2).

The challenge was launched to evaluate variant calling for difficult regions of the human genome. Until recently, the Genome in a Bottle (GIAB) benchmarks did not measure variant calling accuracy across the most difficult 12% of the human genome, which includes many medically relevant genes. To address this, GIAB released an expanded benchmark (v4) for one of its reference samples, HG002, that covers an additional 6.3% of the genome. GIAB then developed expanded benchmarks for two other samples, HG003 and HG004. Before those benchmarks were released, the new precisionFDA challenge was used to assess currently available variant-calling techniques.

The challenge provided short reads from the Illumina NovaSeq, PacBio HiFi reads from the Sequel II System, and long reads from the Oxford Nanopore PromethION for HG002, HG003, and HG004. Competitors were invited to submit calls for HG003 and HG004, which were then evaluated against the not-yet-released “truth” variant calls for those samples. Variant calling accuracy was measured for SNVs and indels in the full genome, in difficult-to-map regions, and in the major histocompatibility complex (MHC).

The best overall performance was achieved using HiFi reads, which are both accurate (99.8%) and long (15-20 kb).  HiFi read accuracy translates into accurate variant calls, and read length improves mappability to difficult regions of the genome.  Equally important were advances in variant calling software, including DeepVariant (see Google AI blog for latest release) and DNAscope, to better model the properties of HiFi reads and utilize the long-range information that HiFi reads provide.

DeepVariant with only HiFi reads achieved 99.9% precision and recall for SNVs and 99.4% precision and recall for indels. In comparison, DeepVariant with Illumina reads had 4.2× more SNV errors but 1.5× fewer indel errors.  The best Oxford Nanopore callset had 3.8× more SNV errors and 58.2× more indel errors (Figure 2).

The precisionFDA contest was an important opportunity to evaluate variant-calling methods, and it demonstrates how HiFi reads provide more comprehensive and accurate variant detection.  We are excited to see how researchers apply this capability to search for new disease genes and to solve rare disease cases that have gone undiagnosed by other approaches.

 

Figure 2. Variant Calling Performance, HG003. Total errors – the sum of SNV and indel false positives (FP) and false negatives (FN) – in a DeepVariant callset from 35× PacBio HiFi read coverage (Sequel II System, Chemistry 2.0); a DeepVariant callset from 35× Illumina NovaSeq; a GATK 4 callset from 35× Illumina NovaSeq; and a PEPPER-DeepVariant callset from 60× ONT PromethION R9.4.1. Performance is measured with hap.py against the Genome in a Bottle small variant benchmark v4.2 used in the precisionFDA Truth Challenge V2. The PacBio HiFi DeepVariant callset had the fewest overall errors of any single-technology callset in the challenge.

Hear Aaron Wenger, a Principal Scientist at PacBio, present a summary of the results from the precisionFDA Truth Challenge V2:

Explore workflows and additional resources on comprehensive variant detection or structural variant detection.

 

Subscribe for blog updates:

Archives

Press Release

Pacific Biosciences Announces New Chief Financial Officer

Monday, September 14, 2020